Summit Therapeutics Inc.
SMMT
$26.20
$0.190.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2,212.43% | 7.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 750.30% | 1.89% | |||
| Operating Income | -750.30% | -1.89% | |||
| Income Before Tax | -799.19% | -2.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -799.19% | -2.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -799.19% | -2.79% | |||
| EBIT | -750.30% | -1.89% | |||
| EBITDA | -750.57% | -1.88% | |||
| EPS Basic | -794.13% | -2.65% | |||
| Normalized Basic EPS | -793.25% | -2.70% | |||
| EPS Diluted | -746.44% | -0.45% | |||
| Normalized Diluted EPS | -793.25% | -2.70% | |||
| Average Basic Shares Outstanding | 0.61% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.61% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||